Email Updates

You are here

AVAC in the News

  • Thirty-six years after a rare lung infection in gay men in Los Angeles heralded the start of the AIDS epidemic, more than half of all people living with HIV are on virus-suppressing treatment. And thousands of people are using Gilead Sciences’ Truvada in a PrEP trial that’s curbing the spread in communities from London to San Francisco.

    August 17, 2017
  • Last fall, Gilead came under fire from community activists for rolling out the DISCOVER trials for Descovy (TAF/FTC) as PrEP without adequately involving community advisors per the Good Participatory Practice (GPP) guidelines. Community advocate and clinical investigator pushback led to some changes in the trial protocol, [but]...according to Jeremiah Johnson, community engagement coordinator for Treatment Action Group (TAG),...other concerns remain.

    August 7, 2017
    The Body
  • Healthcare giant Johnson & Johnson is to take a big step closer to inventing a vaccine for HIV when it publishes the results of a groundbreaking clinical trial this week.

    July 23, 2017
  • As the world's top HIV experts head to Paris for an International AIDS Society meeting, word is we're still playing catch-up with the virus. And if resistance to antiretroviral drugs grows, things will only get worse.

    July 20, 2017
    Deutsche Welle
  • A new report from the United Nations shows promising progress in treating the global HIV/AIDS crisis, but some experts worry President Donald Trump’s policy proposals might turn the trend right back around.

    July 20, 2017
  • Researchers, clinicians, and advocates converging in Paris for the International AIDS Conference 2017 will not only be talking about new HIV treatment and prevention and how to roll out innovative medications in a comprehensive, integrated way, they will also be making a case to funders...."If funders feel the progress we're making, it will create dividends in more ways than one," said International AIDS Society President Linda-Gail Bekker. "We may see some threatened cuts put on hold."

    July 19, 2017
  • The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the US Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become available and how much it will cost.

    July 6, 2017
    The Body
  • Mitchell Warren calls, on National HIV Testing Day, for individuals to get tested, know their status and take appropriate steps to access treatment and prevention. And also for funders and policymakers to support life-saving and cost-saving testing programs that are the cornerstone of a comprehensive, integrated and sustained response to HIV.

    June 27, 2017
  • The US Food and Drug Administration (FDA) has approved the first generic version of emtricitabine/tenofovir disoproxil (Truvada, Gilead Sciences) to both treat and prevent HIV infections in this country, the agency announced today.

    June 9, 2017
  • Medical and health advocacy groups have come out largely in opposition to the Trump administration's proposed cuts in the 2018 budget, with one executive calling it a "disaster" to federal programs and institutions that provide resources to improve health.

    May 24, 2017
    Healthcare Finance